Detailed Narrative
Robust Q3 FY26 Financial Performance
Sastasundar Ventures Limited delivered a strong Q3 FY26, with revenue from operations growing 22% year-on-year to ₹341 crores. Gross margin expanded to 7.6% from 6% in the prior year, driven by an improved product mix and operational efficiencies. The company achieved a significant turnaround in profitability, with EBIT turning positive at ₹1 crore compared to a loss of ₹37 crores in Q3 FY25. For the nine-month period, PAT also turned positive at ₹11 crores, a substantial improvement from a loss of ₹151 crores in 9M FY25.
Strategic Platform Development and Growth Targets
The company's core platforms, Retailer Shakti and SastaSundar B2C, continue to drive growth. Retailer Shakti is already EBITDA positive in January and is targeted to achieve sustainable EBITDA positive performance in FY27, with a goal of 1% EBITDA. SastaSundar B2C is also progressing towards contribution margin positivity in FY27. The Healthbuddy network currently stands at 293 and is projected to grow 50-60% year-on-year, reaching approximately 400 by March 31, FY27.
Launch of JITO Brand and Margin Expansion
Sastasundar has launched its JITO brand, a progressive strategy to distribute generic-generic offerings through its network of 65,000 retail pharmacies. While initial sales are in lakhs, JITO is projected to contribute 2-3% of total revenue next year, growing to 5% in 24 months and 10% in 3-4 years. This brand is expected to significantly enhance gross margins, targeting 30% for JITO products and an overall company gross margin of 9.5-10% with the integration of data and platform revenues.
Capital Efficiency and Strategic Investments
The company emphasizes its capital-efficient model, with total treasury at approximately ₹500 crores. It plans to invest ₹150 crores in building new technology, with ₹50-60 crores already spent and the remaining ₹100 crores to be funded by treasury income over the next 2-3 years. Additionally, ₹10 crores has been invested in an AI-driven SaaS platform called Retail Air, and ₹25 crores per year is budgeted for the AI studio team. These investments are expected to deliver measurable operating leverage benefits from FY27.
Warehouse Expansion and Infrastructure Development
To support rapid growth, Sastasundar is undertaking significant warehouse expansion. An 80,000 square feet additional fulfillment center in West Bengal is expected to be completed within six months, with a ₹10 crore investment. A 1 lakh square feet new warehouse is being built in Noida, expected to take 1.5 years. New facilities are also planned for Guwahati, Lucknow, and Udaipur, each projected for completion within two years.
Corporate Restructuring and Future Outlook
The company plans a significant corporate restructuring, involving a name change to Health X Platform Limited, under which Sastasundar and HealthBuddy will merge. Concurrently, the NBFC business, Microsec Resources, will be demerged and listed separately. This process is expected to be completed in the next financial year, following board approval after FY26 closing. Management also indicated a potential buyback of shares post-merger, having already bought back ₹100 crores from Mitsubishi.